Pietrantonio, Filippo

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 486

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 424

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 398

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 398

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial

Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., et al. (2020) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 334

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 317

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism

Cancer, Hypoxia, and MetabolismLung Cancer Treatments and Mutations

Cited by 299

Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial

Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 280

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 214

Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 208

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 202

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 182

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., et al. (2021) · Cell Death & Differentiation

Gut microbiota and healthCancer, Lipids, and Metabolism

Cited by 172

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchColorectal Cancer Treatments and Studies

Cited by 147

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 134

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Fucà, G., Cohen, R., Lonardi, S., Shitara, K., Elez, M. E., Fakih, M., Chao, J., Klempner, S. J., Emmett, M., Jayachandran, P., et al. (2022) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersIntraperitoneal and Appendiceal Malignancies

Cited by 129

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer

Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Schirripa, M., Nappo, F., Cremolini, C., Salvatore, L., Rossini, D., Bensi, M., Businello, G., Pietrantonio, F., Randon, G., Fucà, G., et al. (2020) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 66

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., et al. (2025) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 51

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 50

Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 24

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial

Siena, S., Sartore-Bianchi, A., Personeni, N., Pietrantonio, F., Germano, G., Amatu, A., Bonoldi, E., Valtorta, E., Barault, L., Di Nicolantonio, F., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 15

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., et al. (2021) · ESMO Open

Neutropenia and Cancer InfectionsColorectal Cancer Treatments and Studies

Cited by 7

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

Tabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 4